Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Autoimmune Disorders

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 77 articles: HTML format

Single Articles

February 2026
1. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
   Ann Neurol. 2026;99:553.
   PubMed    
   
   
   January 2026
2. BOURDETTE D, Silbermann E
   Stop the Spin: Confronting Reporting Bias in Multiple Sclerosis Research.
   Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78126.
   PubMed    
   
   
   
3. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Candal-Pedreira C, Garcia G, et al
   Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials.
   Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78125.
   PubMed     Abstract available
   
   
   
4. PISA M, Lockhart A, Angell T, Avery A, et al
   Topographical Variation of Iron-Rimmed Lesions in the Multiple Sclerosis Brain and Spinal Cord: A Neuropathological Study.
   Ann Neurol. 2026 Jan 18. doi: 10.1002/ana.78113.
   PubMed     Abstract available
   
   
   
5. SMITH C, Greenberg BM, Reynolds J, Mosavi-Hecht R, et al
   A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis.
   Ann Neurol. 2026 Jan 10. doi: 10.1002/ana.78149.
   PubMed     Abstract available
   
   
   
6. CORSTEN CEA, Marques AM, Vinke EJ, de Mol CL, et al
   Brain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis.
   Ann Neurol. 2026 Jan 5. doi: 10.1002/ana.78148.
   PubMed     Abstract available
   
   
   December 2025
7. SABATINO JJ JR, Cree BAC, Hauser SL
   Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78124.
   PubMed    
   
   
   
8. BIRNBAUM G
   New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78121.
   PubMed    
   
   
   
9. WAEDE M, Kingo C, Damsbo K, Joergensen MU, et al
   Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy.
   Ann Neurol. 2025;98:1283-1298.
   PubMed     Abstract available
   
   
   November 2025
10. CHEN J, Su C, Feng L, Wang H, et al
    Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.
    Ann Neurol. 2025 Nov 24. doi: 10.1002/ana.78093.
    PubMed     Abstract available
    
    
    
11. LOREFICE L, Pellecchia MT
    Frailty across Neurological Diseases: Why Sex and Gender Matter.
    Ann Neurol. 2025 Nov 21. doi: 10.1002/ana.78110.
    PubMed     Abstract available
    
    
    
12. ABRAMS AW, Waltz M, Casper TC, Aaen G, et al
    Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.
    Ann Neurol. 2025 Nov 6. doi: 10.1002/ana.78086.
    PubMed     Abstract available
    
    
    October 2025
13. SIMPSON-YAP S, Morwitch E, Tanner SA, Thomson SM, et al
    Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset.
    Ann Neurol. 2025 Oct 10. doi: 10.1002/ana.78043.
    PubMed     Abstract available
    
    
    
14. GHEZZI L, Kosa P, Greenwood M, Alvarez E, et al
    From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.
    Ann Neurol. 2025 Oct 3. doi: 10.1002/ana.78047.
    PubMed     Abstract available
    
    
    
15. FISSE AL, Bonberg N, Beuker C, Pfeuffer C, et al
    Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System-A Multicenter Cohort Study in 163 Patients.
    Ann Neurol. 2025;98:883-893.
    PubMed     Abstract available
    
    
    September 2025
16. BREVILLE G, Benkhoucha M, Rezk A, Tran NL, et al
    Pro-Inflammatory c-Met(+) CD4 T Cells in Multiple Sclerosis.
    Ann Neurol. 2025 Sep 26. doi: 10.1002/ana.78035.
    PubMed     Abstract available
    
    
    
17. SIAVOSHI F, Smith MD, Cassard S, Moreau GB, et al
    Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.
    Ann Neurol. 2025 Sep 19. doi: 10.1002/ana.78044.
    PubMed     Abstract available
    
    
    
18. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
    Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
    Ann Neurol. 2025 Sep 8. doi: 10.1002/ana.78033.
    PubMed     Abstract available
    
    
    
19. ROY B, Chen J, Khani-Habibabadi F, McLaren N, et al
    A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.
    Ann Neurol. 2025 Sep 6. doi: 10.1002/ana.78017.
    PubMed     Abstract available
    
    
    August 2025
20. MANOUCHEHRINIA A, Fitzgerald KC, Salter A, Marrie RA, et al
    Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2025 Aug 7. doi: 10.1002/ana.70020.
    PubMed     Abstract available
    
    
    July 2025
21. KUNCHOK A, Amin M, Ongphichetmetha T, Du M, et al
    Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations.
    Ann Neurol. 2025 Jul 29. doi: 10.1002/ana.27309.
    PubMed     Abstract available
    
    
    
22. CREE BAC, Freedman MS, Gold M, Pfleeger K, et al
    Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
    Ann Neurol. 2025 Jul 23. doi: 10.1002/ana.27262.
    PubMed     Abstract available
    
    
    June 2025
23. SACCO S, Papinutto N, Schoeps VA, Cheng S, et al
    High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
    Ann Neurol. 2025 Jun 24. doi: 10.1002/ana.27298.
    PubMed     Abstract available
    
    
    
24. DISANTO G, Sacco R, Mallucci G, Zecca C, et al
    Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
    Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
    PubMed     Abstract available
    
    
    
25. SABATINO JJ JR, Cree BAC, Hauser SL
    New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
    Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270.
    PubMed     Abstract available
    
    
    April 2025
26. POOLE S, Sisodia N, Koshal K, Henderson K, et al
    Detecting New Lesions Using a Large Language Model: Applications in Real-World Multiple Sclerosis Datasets.
    Ann Neurol. 2025 Apr 25. doi: 10.1002/ana.27251.
    PubMed     Abstract available
    
    
    
27. MURARO PA, Zito A, Signori A, Sormani MP, et al
    Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
    Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247.
    PubMed     Abstract available
    
    
    
28. PANSIERI J, Pisa M, Yee S, Gutnikova A, et al
    Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex.
    Ann Neurol. 2025 Apr 8. doi: 10.1002/ana.27231.
    PubMed     Abstract available
    
    
    February 2025
29. GUO K, Peng F, Liu J, Long Y, et al
    Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
    Ann Neurol. 2025 Feb 24. doi: 10.1002/ana.27218.
    PubMed     Abstract available
    
    
    
30. ABBADESSA G, Nagano A, Hametner S, Howell O, et al
    Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics.
    Ann Neurol. 2025 Feb 14. doi: 10.1002/ana.27216.
    PubMed     Abstract available
    
    
    
31. HASHEMI E, Srivastava IN, Aguirre A, Yoseph ET, et al
    A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets.
    Ann Neurol. 2025;97:296-312.
    PubMed     Abstract available
    
    
    
32. PAPADOPOULOS D, Magliozzi R, Bandiera S, Cimignolo I, et al
    Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.
    Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195.
    PubMed     Abstract available
    
    
    January 2025
33. MARGONI M, Storelli L, Pagani E, Preziosa P, et al
    Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.
    Ann Neurol. 2025 Jan 18. doi: 10.1002/ana.27180.
    PubMed     Abstract available
    
    
    December 2024
34. BRIER MR, Judge B, Ying C, Salter A, et al
    Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
    Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165.
    PubMed     Abstract available
    
    
    
35. HELBIG I, Ganesan S
    NORSE, FIRES, and a Polygenic Trickle of Autoimmunity.
    Ann Neurol. 2024 Dec 7. doi: 10.1002/ana.27148.
    PubMed    
    
    
    November 2024
36. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
    Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
    Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
    PubMed     Abstract available
    
    
    
37. CABALLERO-AVILA M, Martin-Aguilar L, Pascual-Goni E, Michael MR, et al
    Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
    Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142.
    PubMed     Abstract available
    
    
    
38. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
    Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
    Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
    PubMed     Abstract available
    
    
    
39. MEUTH SG, Wolff S, Muck A, Willison A, et al
    Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
    Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
    PubMed     Abstract available
    
    
    October 2024
40. WANG W, Yin J
    Coexistence of Acute Cerebral Infarction and Reversible Posterior Encephalopathy Syndrome in a Patient with Hashimoto's Thyroiditis.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27120.
    PubMed    
    
    
    
41. JANG Y, Hong SE, Ahn SH, Mon SY, et al
    Polygenic Landscape of Cryptogenic New-Onset Refractory Status Epilepticus: A Comprehensive Whole-Genome Sequencing Study.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27100.
    PubMed     Abstract available
    
    
    
42. ALZAMANAN F, Ding Y, Harroud A
    Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
    Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
    PubMed     Abstract available
    
    
    
43. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
    RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
    PubMed     Abstract available
    
    
    
44. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
    Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
    PubMed     Abstract available
    
    
    
45. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
    Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
    PubMed     Abstract available
    
    
    
46. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
    Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
    Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
    PubMed     Abstract available
    
    
    
47. SUZUKI S, Utsugisawa K
    MuSK-Myasthenia Gravis and Cancer.
    Ann Neurol. 2024 Oct 8. doi: 10.1002/ana.27094.
    PubMed    
    
    
    
48. FALSO S, Iorio R
    Reply to "MuSK-Myasthenia Gravis and Cancer".
    Ann Neurol. 2024 Oct 4. doi: 10.1002/ana.27091.
    PubMed    
    
    
    September 2024
49. FADDA G, Banwell B, Elliott C, Fetco D, et al
    Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
    Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
    PubMed     Abstract available
    
    
    August 2024
50. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    PubMed     Abstract available
    
    
    July 2024
51. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    PubMed     Abstract available
    
    
    
52. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    PubMed     Abstract available
    
    
    
53. FALSO S, Gessi M, Marini S, Benvenuto R, et al
    Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.
    Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033.
    PubMed     Abstract available
    
    
    
54. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    PubMed     Abstract available
    
    
    
55. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    
56. GUO A, Zhang Z, Dong GH, Su L, et al
    Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2024;96:194-203.
    PubMed     Abstract available
    
    
    June 2024
57. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    PubMed     Abstract available
    
    
    May 2024
58. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    PubMed     Abstract available
    
    
    
59. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    PubMed     Abstract available
    
    
    April 2024
60. GILLIGAN M, Lesnick CE, Guo Y, Bradshaw MJ, et al
    Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis.
    Ann Neurol. 2024 Apr 18. doi: 10.1002/ana.26943.
    PubMed     Abstract available
    
    
    
61. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    PubMed     Abstract available
    
    
    March 2024
62. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    PubMed     Abstract available
    
    
    
63. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    PubMed     Abstract available
    
    
    
64. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    PubMed     Abstract available
    
    
    February 2024
65. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    PubMed     Abstract available
    
    
    
66. SHU Y, Huang R, Li Q, Lu Y, et al
    Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with HLA-A*3303 and HLA-DPB1*0501.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899.
    PubMed     Abstract available
    
    
    
67. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    PubMed     Abstract available
    
    
    December 2023
68. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    PubMed     Abstract available
    
    
    
69. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    PubMed     Abstract available
    
    
    
70. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    PubMed    
    
    
    
71. DUCHOW A, Bellmann-Strobl J, Friede T, Aktas O, et al
    Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26858.
    PubMed     Abstract available
    
    
    
72. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    PubMed    
    
    
    
73. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    PubMed     Abstract available
    
    
    November 2023
74. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    PubMed     Abstract available
    
    
    October 2023
75. MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al
    Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
    Ann Neurol. 2023;94:727-735.
    PubMed     Abstract available
    
    
    September 2023
76. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    PubMed     Abstract available
    
    
    
77. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum